Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | BCL2 | P10415 | 2/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA3 | P07451 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | CA6 | P23280 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8282658 | 0.91 | ALDH1A1 (0.56) | ALDH1A1TSHRDNM1LMNABCL2 | |
| SCHEMBL15182738 | 0.89 | ALDH1A1 (0.41) | ALDH1A1TSHRDNM1LMNABCL2 | |
| SCHEMBL15182739 | 0.89 | ALDH1A1 (0.41) | ALDH1A1TSHRDNM1LMNABCL2 | |
| SCHEMBL17523760 | 0.88 | ALDH1A1 (0.61) | ALDH1A1TSHRDNM1LMNAHTR1A | |
| SCHEMBL17523775 | 0.88 | ALDH1A1 (0.61) | ALDH1A1TSHRDNM1LMNAHTR1A | |
| SCHEMBL23873076 | 0.88 | ALDH1A1 (0.61) | ALDH1A1TSHRDNM1LMNAHTR1A | |
| SCHEMBL12830232 | 0.88 | ALDH1A1 (0.61) | ALDH1A1TSHRDNM1LMNAHTR1A | |
| SCHEMBL20646820 | 0.88 | ALDH1A1 (0.61) | ALDH1A1TSHRDNM1LMNAHTR1A | |
| SCHEMBL25055188 | 0.84 | CA12 (0.55) | ALDH1A1TSHRLMNAHTR1ADRD2 | |
| SCHEMBL17225210 | 0.81 | CHRM2 (0.39) | TSHRLMNACA12CA2CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 383 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-11834451-B2 | Compositions and methods for inhibiting virus protein 2C activity and for preventing and treating non-polio enterovirus infection | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834450-B2 | Compounds having ((3-nitrophenyl)sulfonyl)acetamide as BCL-2 inhibitors | Eil Therapeutics, Inc. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834450-B2 | Compounds having ((3-nitrophenyl)sulfonyl)acetamide as BCL-2 inhibitors | Eil Therapeutics, Inc. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834412-B2 | Derivatives of aryl hydrocarbon receptor agonists | AZORA THERAPEUTICS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834451-B2 | Compositions and methods for inhibiting virus protein 2C activity and for preventing and treating non-polio enterovirus infection | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2023-12-05 | — | — | US | disclosed |
| US-11833122-B2 | Aminonaphthoquinone compounds for treatment and/or prevention of fibrosis diseases | CALGENT BIOTECHNOLOGY CO., LTD. (TW) | 2023-12-05 | — | — | US | disclosed |
| US-20230372537-A1 | LIPID NANOPARTICLE FORMULATIONS | ACUITAS THERAPEUTICS INC (CA) | 2023-11-23 | — | — | US | disclosed |
| US-20230365542-A1 | Selective Agonists of 5-HT2A Receptor and Methods of Use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230365542-A1 | Selective Agonists of 5-HT2A Receptor and Methods of Use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-11-16 | — | — | US | disclosed |
| US-20070066573-A1 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | ELI LILLY AND COMPANY | 2007-03-22 | — | — | US | disclosed |
| US-7192955-B2 | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same | AVANIR PHARMACEUTICALS (US) | 2007-03-20 | — | — | US | disclosed |
| US-20070043053-A1 | Pyrrolo-triazine aniline compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-02-22 | — | — | US | disclosed |
| US-20070043045-A1 | Novel high affinity thiophene-based and furan-based kinase ligands | SCHERING CORPORATION | 2007-02-22 | — | — | US | disclosed |
| US-20070021440-A1 | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same | AVANIR PHARMACEUTICALS | 2007-01-25 | — | — | US | disclosed |
| US-7160883-B2 | Pyrrolo-triazine aniline compounds useful as kinase inhibitors | BRISTOL-MYERS-SQUIBB COMPANY (US) | 2007-01-09 | — | — | US | disclosed |
| US-7157582-B2 | Selective iGluR5 receptor antagonists | ELI LILLY AND COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
| CN-1249068-C | Chemical products suitable as cocatalysts, their preparation and their use in catalyst systems for the preparation of polyolefins | BASELL POLYOLEFINE GMBH (DE) | 2006-04-05 | — | — | CN | disclosed |
| CN-1433339-A | New catalyst system and application thereof | BASELL POLYROPYLEN GMBH (DE) | 2003-07-30 | — | — | CN | disclosed |
| CN-1427842-A | Chemical products suited for use as co-catalysts, method for preparation thereof and their use in catalyst systems for producing polyolefins | BASELL POLYOLEFINE GMBH (DE) | 2003-07-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365542-A1 | Selective Agonists of 5-HT2A Receptor and Methods of Use | HTR2A, HTR2C, HTR2B | ALDH1A1 857/4885TSHR 242/4885DNM1 3782/4885 |
| US-11834450-B2 | Compounds having ((3-nitrophenyl)sulfonyl)acetamide as BCL-2 inhibitors | BCL2, BCL2A1, BCL2L1 | ALDH1A1 722/4885TSHR 3891/4885DNM1 1907/4885 |
| US-11834412-B2 | Derivatives of aryl hydrocarbon receptor agonists | AHR, ARNT, NR4A1 | ALDH1A1 750/4885TSHR 21/4885DNM1 4269/4885 |
| US-20230372537-A1 | LIPID NANOPARTICLE FORMULATIONS | LIPA, PLIN3, PLIN1 | ALDH1A1 1911/4885TSHR 3943/4885DNM1 688/4885 |
| US-20070021440-A1 | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same | MIF, MSR1, MMP12 | ALDH1A1 2081/4885TSHR 2175/4885DNM1 4309/4885 |
| US-20070043053-A1 | Pyrrolo-triazine aniline compounds useful as kinase inhibitors | PLK2, CDK2, MAP3K15 | ALDH1A1 3629/4885TSHR 558/4885DNM1 4287/4885 |
| US-11833122-B2 | Aminonaphthoquinone compounds for treatment and/or prevention of fibrosis diseases | KEAP1, GOT2, COL1A1 | ALDH1A1 106/4885TSHR 4773/4885DNM1 2085/4885 |
| US-20070043045-A1 | Novel high affinity thiophene-based and furan-based kinase ligands | CDKL2, CDK2, CDKL1 | ALDH1A1 4225/4885TSHR 3195/4885DNM1 2215/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | ALDH1A1 128/4885TSHR 728/4885DNM1 2384/4885 |
| US-20070066573-A1 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | GRIN1, GRIN3A, GRIK5 | ALDH1A1 2211/4885TSHR 315/4885DNM1 119/4885 |
| US-11834451-B2 | Compositions and methods for inhibiting virus protein 2C activity and for preventing and treating non-polio enterovirus infection | GTF3C3, VDAC3, GTF3C5 | ALDH1A1 4182/4885TSHR 4249/4885DNM1 3997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.